Published in Cancer Res on September 26, 2013
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. Oncotarget (2014) 0.92
PP2A: The Wolf in Sheep's Clothing? Cancers (Basel) (2015) 0.85
Mysteries of TGF-β Paradox in Benign and Malignant Cells. Front Oncol (2014) 0.82
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget (2015) 0.78
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. EMBO Rep (2017) 0.75
The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation. Nucleic Acids Res (2016) 0.75
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev (2000) 11.49
CIP2A inhibits PP2A in human malignancies. Cell (2007) 5.28
The DNA damage response and cancer therapy. Nature (2012) 5.25
Rules for making human tumor cells. N Engl J Med (2002) 4.84
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res (2010) 4.44
From promiscuity to precision: protein phosphatases get a makeover. Mol Cell (2009) 4.17
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med (2010) 2.44
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell (2008) 2.17
Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One (2008) 2.12
PP2A: unveiling a reluctant tumor suppressor. Cell (2007) 2.12
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90
The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell (2010) 1.90
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci U S A (2008) 1.74
Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci U S A (2007) 1.62
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene (2010) 1.62
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene (2011) 1.52
Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res (2011) 1.41
SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev (2008) 1.34
Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem (2005) 1.29
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene (2012) 1.23
A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1. Genome Biol (2011) 1.21
Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov (2013) 1.17
An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation. J Exp Med (2012) 1.15
Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells - differentiation pattern of nontumorigenic cell-lines. Int J Oncol (1995) 1.12
ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One (2011) 1.05
Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene (2010) 1.05
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res (2012) 1.04
Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol (2012) 1.04
SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells. J Biol Chem (2011) 1.02
CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PLoS One (2012) 0.96
The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer (2010) 0.95
Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene (2011) 0.93
Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene (2011) 0.85
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
CIP2A inhibits PP2A in human malignancies. Cell (2007) 5.28
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J (2007) 3.91
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
A practical comparison of methods for detecting transcription factor binding sites in ChIP-seq experiments. BMC Genomics (2009) 2.70
Integrated network analysis platform for protein-protein interactions. Nat Methods (2008) 2.63
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
GOlorize: a Cytoscape plug-in for network visualization with Gene Ontology-based layout and coloring. Bioinformatics (2006) 2.37
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology (2002) 2.19
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med (2010) 1.94
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov (2013) 1.93
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell (2008) 1.82
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet (2012) 1.74
Manufactured nanomaterials: categorization and approaches to hazard assessment. Arch Toxicol (2014) 1.71
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.65
CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene (2005) 1.63
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58
Improving missing value estimation in microarray data with gene ontology. Bioinformatics (2005) 1.57
IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration. J Cell Sci (2008) 1.56
Systematic construction of gene coexpression networks with applications to human T helper cell differentiation process. Bioinformatics (2007) 1.54
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res (2002) 1.54
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res (2009) 1.54
Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol (2012) 1.53
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res (2013) 1.51
Zebrafish embryos as an alternative to animal experiments--a commentary on the definition of the onset of protected life stages in animal welfare regulations. Reprod Toxicol (2011) 1.51
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res (2003) 1.50
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet (2008) 1.46
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res (2005) 1.46
Single-step Strep-tag purification for the isolation and identification of protein complexes from mammalian cells. Proteomics (2005) 1.45
Mechanisms of MYC stabilization in human malignancies. Cell Cycle (2007) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Integrating probe-level expression changes across generations of Affymetrix arrays. Nucleic Acids Res (2005) 1.42
miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer (2010) 1.42
Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res (2007) 1.41
Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.40
Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc Natl Acad Sci U S A (2005) 1.40
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
Genetic variants and their interactions in the prediction of increased pre-clinical carotid atherosclerosis: the cardiovascular risk in young Finns study. PLoS Genet (2010) 1.39
Intussusception and spontaneous amputation of the esophagus. J Thorac Cardiovasc Surg (2002) 1.38
Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol (2002) 1.35
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res (2005) 1.34
Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res (2010) 1.33
Probabilistic analysis of gene expression measurements from heterogeneous tissues. Bioinformatics (2010) 1.31
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31
The DEXD/H-box RNA helicase RHII/Gu is a co-factor for c-Jun-activated transcription. EMBO J (2002) 1.30
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer (2006) 1.30
Androgen regulation of micro-RNAs in prostate cancer. Prostate (2010) 1.30
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol (2013) 1.30
The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology (2012) 1.29
Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet (2010) 1.29
Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity (2010) 1.28
Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer (2002) 1.28
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res (2009) 1.27
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol (2006) 1.27
DNA damage induces downregulation of histone gene expression through the G1 checkpoint pathway. EMBO J (2004) 1.27
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res (2013) 1.26
Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc Natl Acad Sci U S A (2012) 1.26
Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res (2012) 1.25
Slow oscillation electrical brain stimulation during waking promotes EEG theta activity and memory encoding. Proc Natl Acad Sci U S A (2009) 1.24
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Identification of tumor epithelium and stroma in tissue microarrays using texture analysis. Diagn Pathol (2012) 1.23
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages. PLoS Pathog (2011) 1.22
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
Alignment of LC-MS images, with applications to biomarker discovery and protein identification. Proteomics (2008) 1.22
Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene (2002) 1.22